Related Experiment Videos
In-vitro evaluation of povidone-iodine and chlorhexidine against methicillin-resistant Staphylococcus aureus
1Department of Microbiology, Gartnavel General Hospital, Glasgow, UK.
Abstract:
The in-vitro activity of povidone-iodine (PVP-I) and chlorhexidine (CHX) against 33 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) was evaluated by a quantitative suspension test method. Bactericidal potency was measured by the logarithmic reduction factors (LRFs) achieved with each strain, tested at dilutions 25-800 over exposure times 30-300 s using a challenge of approximately 10(7) colony forming units (cfu) ml-1. The mean LRFs achieved over all dilutions, times and strains were significantly higher for PVP-I than CHX. PVP-I exhibited a superior killing effect whether measured by rate of kill or final LRF achieved. This difference was highly significant as judged by analysis of variance (P less than 0.001). Full efficacy of an antiseptic has been defined as a safe LRF greater than five. Over the dilution range 25-200 this was achieved by CHX with only three of 33 strains. In contrast, PVP-I achieved full efficacy with all 33 strains.
Insights
Povidone-iodine (PVP-I) demonstrated superior in-vitro bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) compared to chlorhexidine (CHX). PVP-I achieved full efficacy against all MRSA strains tested, unlike CHX.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Agents
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to its resistance to common antibiotics.
- Effective disinfection and antisepsis are crucial in controlling MRSA infections.
- Povidone-iodine (PVP-I) and chlorhexidine (CHX) are widely used antiseptics, but their comparative efficacy against MRSA requires detailed evaluation.
Purpose of the Study:
- To quantitatively compare the in-vitro bactericidal activity of PVP-I and CHX against clinical isolates of MRSA.
- To determine the efficacy of both antiseptics at various dilutions and exposure times.
- To assess the achievement of 'full efficacy' (logarithmic reduction factor > 5) for each agent.
Main Methods:
- A quantitative suspension test method was employed to evaluate PVP-I and CHX.
- Thirty-three clinical MRSA isolates were challenged with approximately 10(7) colony forming units (cfu) ml-1.
- Bactericidal potency was measured by logarithmic reduction factors (LRFs) across dilutions (25-800) and exposure times (30-300 s).
Main Results:
- PVP-I achieved significantly higher mean LRFs than CHX across all tested conditions (P < 0.001).
- PVP-I exhibited a superior killing rate and a greater final LRF compared to CHX.
- Full efficacy (LRF > 5) was achieved by PVP-I against all 33 MRSA strains, whereas CHX achieved this with only 3 strains at dilutions of 25-200.
Conclusions:
- PVP-I demonstrates superior in-vitro bactericidal efficacy against MRSA compared to CHX.
- PVP-I is a more effective antiseptic agent for MRSA eradication under the tested conditions.
- These findings support the use of PVP-I for disinfection and antisepsis in settings with MRSA prevalence.